Day CP - Search Results

1

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.

Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Govaere O, et al. Among authors: day cp. Sci Transl Med. 2020 Dec 2;12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448. Sci Transl Med. 2020. PMID: 33268509 Free article.

2

Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver.

Teli MR, Day CP, Burt AD, Bennett MK, James OF. Teli MR, et al. Among authors: day cp. Lancet. 1995 Oct 14;346(8981):987-90. doi: 10.1016/s0140-6736(95)91685-7. Lancet. 1995. PMID: 7475591

3

The natural history of nonalcoholic fatty liver: a follow-up study.

Teli MR, James OF, Burt AD, Bennett MK, Day CP. Teli MR, et al. Among authors: day cp. Hepatology. 1995 Dec;22(6):1714-9. Hepatology. 1995. PMID: 7489979

4

Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis.

Grove J, Daly AK, Bassendine MF, Day CP. Grove J, et al. Among authors: day cp. Hepatology. 1997 Jul;26(1):143-6. doi: 10.1002/hep.510260119. Hepatology. 1997. PMID: 9214463

5

Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance.

Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M. Day CP, et al. Diabetologia. 1998 Apr;41(4):430-4. doi: 10.1007/s001250050926. Diabetologia. 1998. PMID: 9562347

6

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Smith BC, et al. Among authors: day cp. Hepatology. 1998 Jun;27(6):1695-9. doi: 10.1002/hep.510270631. Hepatology. 1998. PMID: 9620344

7

No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis.

Zappala F, Grove J, Watt FE, Daly AK, Day CP, Bassendine MF, Jones DE. Zappala F, et al. Among authors: day cp. J Hepatol. 1998 May;28(5):820-3. doi: 10.1016/s0168-8278(98)80232-8. J Hepatol. 1998. PMID: 9625317

8

The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype.

Grove J, Brown AS, Daly AK, Bassendine MF, James OF, Day CP. Grove J, et al. Among authors: day cp. Pharmacogenetics. 1998 Aug;8(4):335-42. doi: 10.1097/00008571-199808000-00007. Pharmacogenetics. 1998. PMID: 9731720

9

The inheritance of alcoholic liver disease.

Bassendine MF, Day CP. Bassendine MF, et al. Among authors: day cp. Baillieres Clin Gastroenterol. 1998 Jun;12(2):317-35. doi: 10.1016/s0950-3528(98)90137-3. Baillieres Clin Gastroenterol. 1998. PMID: 9890075 Review.

10

Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK. Fairbrother KS, et al. Among authors: day cp. Pharmacogenetics. 1998 Dec;8(6):543-52. doi: 10.1097/00008571-199812000-00011. Pharmacogenetics. 1998. PMID: 9918138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

292 results

Search Page